TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27323447

Group type: EXPERIMENTAL
Intervention: Oblique needling combined with Tuina (Acu+ Tuina)
Number of subjects: 120
Study: 25042422

Group type: EXPERIMENTAL
Intervention: Progressive scapular strengthening exercises for 12 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 59
Study: 24195623

Group type: EXPERIMENTAL
Intervention: 100 mg Lactobacillus gasseri OLL2809
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 100 mg Lactobacillus gasseri OLL2809 + 900 mg α-lactalbumin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 21824504

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 88

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Expectation of caffeinated coffee
Number of subjects: 88

Group type: COMPARATOR
Intervention: Expectation of decaffeinated coffee
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Caffeine (both actual and expected)
Number of subjects: 88
Study: 18460201

Group type: EXPERIMENTAL
Intervention: Self-management programme (cognitive-behavioural, manual based)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Self-management programme
Number of subjects: 140

Group type: COMPARATOR
Intervention: Information only control procedure
Number of subjects: 140
Study: 16762862

Group type: EXPERIMENTAL
Intervention: Needling at Baihui(DU20), Shuigou(DU26) and Shenmen(HT7)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Routine acupoints for hemiplegia (control group)
Number of subjects: 10
Study: 12663512

Group type: EXPERIMENTAL
Intervention: Kiwifruit supplementation (specific dosage not mentioned) for 3-week periods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kiwifruit supplementation (specific dosage not mentioned)
Number of subjects: 0
Study: 10887107

Group type: EXPERIMENTAL
Intervention: Infusion of genetically modified CD8(+) T cells (10(10) cells)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Second series of infusions of both CD4(+) and CD8(+) T cells engineered to express the chimeric receptor, costimulated ex vivo with beads coated with anti‐CD3 and anti‐CD28
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of genetically modified HIV‐antigen‐specific T cells
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Infusion of modified CD4(+) and CD8(+) T cells together after ex vivo costimulation
Number of subjects: 2
Study: 8813788

Group type: EXPERIMENTAL
Intervention: High-dose preoperative radiotherapy (5 x 5 Gy)
Number of subjects: 1399

Group type: COMPARATOR
Intervention: No preoperative radiotherapy
Number of subjects: 1399

Group type: EXPERIMENTAL
Intervention: Four-portal technique to a limited volume
Number of subjects: 1399
Study: 1551634

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha (5 million U/m2, three times a week for 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha
Number of subjects: 60
Study: 2860044

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study: 31025930

Group type: EXPERIMENTAL
Intervention: tocilizumab 8 mg/kg intravenously at study begin and weeks 4, 8, and 12
Number of subjects: 519

Group type: COMPARATOR
Intervention: rituximab 1000 mg at weeks 16 and 18
Number of subjects: 519
Study: 30334433

Group type: EXPERIMENTAL
Intervention: Oral Probiotics
Number of subjects: 0
Study: 27155493

Group type: EXPERIMENTAL
Intervention: PCV13 plus trivalent inactivated influenza vaccine
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Revaccination with PCV13
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Initial vaccination with PCV13
Number of subjects: 1116
Study: 23528191

Group type: EXPERIMENTAL
Intervention: Religiosity assessed before alcohol consumption questions
Number of subjects: 301

Group type: COMPARATOR
Intervention: Religiosity assessed after alcohol consumption questions
Number of subjects: 301
Study: 22330975

Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nonoperative treatment (short leg cast or brace and protected weight bearing for 6 weeks)
Number of subjects: 81
Study: 21164552

Group type: EXPERIMENTAL
Intervention: Interactive video game stationary cycling (GameBike)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stationary cycling to music
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 30
Study: 18044288

Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol 2 mg/kg
Number of subjects: 120
Study: 16248728

Group type: EXPERIMENTAL
Intervention: Causal judgment task with revaluation of cue A (A+ and A-)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Within-compound associations
Number of subjects: 0
Study: 11790236

Group type: EXPERIMENTAL
Intervention: High-dose creatine (150 mg/kg daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10628186

Group type: EXPERIMENTAL
Intervention: Provitamin A carotenoids in dark green, leafy vegetables (DGLV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pure chemical beta-carotene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low vitamin A fare
Number of subjects: 0
Study: 8720287

Group type: COMPARATOR
Intervention: Ribavirin alone (15 mg/kg daily for 6 months)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Interferon alone (3 MU thrice weekly for 6 months)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Interferon plus ribavirin (at above doses)
Number of subjects: 45
Study: 1451730

Group type: EXPERIMENTAL
Intervention: 0.07 mg digitoxin o.d. for up to 58 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: 25 mg oral captopril b.d. (concomitant administration)
Number of subjects: 12
Study: 6331480

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril + Naloxone
Number of subjects: 9
Study: 31201177

Group type: EXPERIMENTAL
Intervention: Telephone-based coaching for patients experiencing depression, anxiety, or at-risk drinking
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Expert psychiatric recommendations
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Organizational adoption and implementation of the study
Number of subjects: 23
Study: 29128648

Group type: EXPERIMENTAL
Intervention: ED-initiated Screening, Brief Intervention, and Referral for Treatment (SBIRT) focused on HTN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ED-initiated SBIRT coupled with a Post-Acute Care Hypertension Transition Consultation by ED Clinical Pharmacists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26179360

Group type: EXPERIMENTAL
Intervention: Insulin degludec and insulin degludec/insulin aspart
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Basal‐oral therapy
Number of subjects: 536

Group type: COMPARATOR
Intervention: Type 1 diabetes
Number of subjects: 536

Group type: COMPARATOR
Intervention: Type 2 diabetes multiple daily injections
Number of subjects: 536
Study: 25294380

Group type: EXPERIMENTAL
Intervention: Diarrhea-predominant IBS (D-IBS) patients
Number of subjects: 62
Study: 22471899

Group type: EXPERIMENTAL
Intervention: Topical fucidic acid plus betamethasone valerate cream
Number of subjects: 25

Group type: COMPARATOR
Intervention: Topical fucidic acid (control group)
Number of subjects: 25
Study: 19963314

Group type: EXPERIMENTAL
Intervention: Use of a nautical inclinometer and a plastic, double-equilateral triangle with an 8-cm-long border for positioning and port placement during RALP
Number of subjects: 0
Study: 17915970

Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 62

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 62
Study: 15610070

Group type: EXPERIMENTAL
Intervention: Bosentan (500 mg orally 2 hours before ischaemia)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 13
Study: 12392582

Group type: EXPERIMENTAL
Intervention: Subcutaneous midazolam (0.1 mg kg‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous midazolam (0.1 mg kg‐1)
Number of subjects: 18
Study: 10427921

Group type: EXPERIMENTAL
Intervention: HEMA IOL (Hydroview)
Number of subjects: 232
Study: 7493374

Group type: EXPERIMENTAL
Intervention: 131I-labeled hMN-14 IgG (8 to 30 mCi, 0.5 to 20.0 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 131I-labeled mMN-14 IgG
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: hMN-14 (3 injections)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tumor radiation absorbed dose
Number of subjects: 19
Study: 2372154

Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine every 6 h for 36 h
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10 mg morphine every 6 h for 36 h
Number of subjects: 50
Study: 6765526

Group type: EXPERIMENTAL
Intervention: Human insulin (recombinant DNA)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Purified pork insulin preparation (regular and NPH insulin)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 131

Group type: COMPARATOR
Intervention: Purified beef insulin (regular and NPH insulin)
Number of subjects: 131
Study: 30844611

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 2376

Group type: COMPARATOR
Intervention: IFN β‐1a
Number of subjects: 2376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2376
Study: 29911875

Group type: EXPERIMENTAL
Intervention: Competitive interaction
Number of subjects: 220

Group type: COMPARATOR
Intervention: Noncompetitive interaction
Number of subjects: 220
Study: 29231294

Group type: EXPERIMENTAL
Intervention: Acupressure at Neiguan (PC 6) combined with press needles
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupressure at Neiguan (PC 6)
Number of subjects: 120
Study: 25654959

Group type: EXPERIMENTAL
Intervention: Levofloxacin (LFX) 500 mg o.d. with scaling and root planing (SRP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo with scaling and root planing (SRP)
Number of subjects: 69
Study: 21672162

Group type: EXPERIMENTAL
Intervention: Periodontal dressing applied after scaling and root planning (SRP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No periodontal dressing (Control group)
Number of subjects: 30
Study: 19106241

Group type: EXPERIMENTAL
Intervention: Higher fat and saturated fat intake
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Lower carbohydrate intake
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Higher insulin dose
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Substitution of fat for carbohydrate
Number of subjects: 532
Study: 17454224

Group type: EXPERIMENTAL
Intervention: L-arginine (20g/500 mL intravenously daily for 5 days followed by 4 g/day orally for 2 weeks)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 74
Study: 15253854

Group type: EXPERIMENTAL
Intervention: Attitudes to Alternative Medicine Scale (pre-proving)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Attitudes to Alternative Medicine Scale (post-proving)
Number of subjects: 206
Study: 11238428

Group type: EXPERIMENTAL
Intervention: Information, education and communication activities (IEC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IEC interventions with improved treatment of STDs
Number of subjects: 36

Group type: COMPARATOR
Intervention: Community development activities unrelated to HIV
Number of subjects: 36
Study: 9678725

Group type: EXPERIMENTAL
Intervention: Rescreening of Pap smear slides
Number of subjects: 0
Study: 8202905

Group type: COMPARATOR
Intervention: Chinese
Number of subjects: 2868

Group type: EXPERIMENTAL
Intervention: Malays
Number of subjects: 2868

Group type: EXPERIMENTAL
Intervention: Indians
Number of subjects: 2868
Study: 2660551

Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g B.I.D.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo/Sucralfate H.S.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 30919704

Group type: EXPERIMENTAL
Intervention: Exposure to 15, 25, and 46 ng/m3 Der p1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 31169045

Group type: EXPERIMENTAL
Intervention: Microswitch intervention
Number of subjects: 6
Study: 28537325

Group type: EXPERIMENTAL
Intervention: Total Protein (TP) intake
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Animal Protein (AP) intake
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Plant Protein (PP) intake
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Calcium 1000 mg/d and cholecalciferol 800 IU for 3 years (intervention group)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Total Protein (TP) intake in active women
Number of subjects: 554
Study: 25482425

Group type: EXPERIMENTAL
Intervention: 200 mg FXI‐ASO
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 300 mg FXI‐ASO
Number of subjects: 300

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 300
Study: 23692550

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training Group (WBVTG), n=26, undergoing three sessions per week for a total of 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (CG), n=25, without intervention
Number of subjects: 60
Study: 21714890

Group type: EXPERIMENTAL
Intervention: Encapsulated juice powder concentrates (with added berry powders)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Encapsulated juice powder concentrates (without added berry powders)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Encapsulated juice powder concentrates (with and without added berry powders)
Number of subjects: 64
Study: 19366271

Group type: EXPERIMENTAL
Intervention: Candesartan/HCTZ 32/25 mg
Number of subjects: 1524

Group type: COMPARATOR
Intervention: Candesartan 32 mg
Number of subjects: 1524

Group type: COMPARATOR
Intervention: HCTZ 25 mg
Number of subjects: 1524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1524
Study: 16712531

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation attempted by paramedics without appropriate drugs to facilitate intubation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intubation facilitated by sedative drugs (but not relaxant drugs).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid sequence intubation for comatose patients transported by helicopter.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of waveform capnography in intubated head injury patients.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rapid transport to hospital without intubation for road-based paramedics.
Number of subjects: 0
Study: 14625264

Group type: EXPERIMENTAL
Intervention: 15 g of alcohol per day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 30 g of alcohol per day
Number of subjects: 53
Study: 11046203

Group type: EXPERIMENTAL
Intervention: Hetastarch (15 ml/kg, 6%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Albumin (15 ml/kg, 5%)
Number of subjects: 11
Study: 9277655

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Pneumoperitoneum
Number of subjects: 57
Study: 8370687

Group type: EXPERIMENTAL
Intervention: Pamidronate (APD) 30 mg, iv, daily for 2 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2942116

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol and ipratropium (combined treatment)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Nebulised doses (both treatments)
Number of subjects: 138
Study: 29080906

Group type: EXPERIMENTAL
Intervention: mCPP (30mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27663694

Group type: EXPERIMENTAL
Intervention: Mainstream mask capnography system (cap‐ONE)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Side stream sampling nasal cannula capnography (NC)
Number of subjects: 39
Study: 24820639

Group type: EXPERIMENTAL
Intervention: Bayesian method based on subgroup analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian method based on regression model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression-based method
Number of subjects: 0
Study: 22808932

Group type: EXPERIMENTAL
Intervention: Home-based yoga program
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Home-based yoga program (good adherence)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 20180613

Group type: EXPERIMENTAL
Intervention: Antidepressants (sertraline or citalopram) with or without cognitive behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapy (aerobic exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for depression
Number of subjects: 0
Study: 18351428

Group type: EXPERIMENTAL
Intervention: Higher testosterone levels
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Higher testosterone levels with vitamin D plus calcium supplementation
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Higher DHEA-S levels (in women)
Number of subjects: 445
Study: 15972618

Group type: EXPERIMENTAL
Intervention: G80 (80% 1RM)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: G50 (50% 1RM)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: G20 (20% 1RM)
Number of subjects: 112

Group type: COMPARATOR
Intervention: CON (nontraining control group)
Number of subjects: 112
Study: 12923507

Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomy
Number of subjects: 93
Study: 10229886

Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Wire fixation
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both groups (Rigid and Wire fixation)
Number of subjects: 117
Study: 8561153

Group type: EXPERIMENTAL
Intervention: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 1 day (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 3 days (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 5 days (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 7 days (n=10)
Number of subjects: 40
Study: 1888322

Group type: EXPERIMENTAL
Intervention: Behavioral treatment (for treated phobics)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No treatment (for untreated phobics)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No treatment (for no-fear controls)
Number of subjects: 57
Study: 7036285

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: BCG plus allogeneic tumor cells
Number of subjects: 52

Group type: COMPARATOR
Intervention: No further therapy (Control)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Immunotherapy (combined BCG arms)
Number of subjects: 52
Study: 31568890

Group type: EXPERIMENTAL
Intervention: Electrical nerve stimulation (ENS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional loco-regional anesthesia (Local group)
Number of subjects: 52
Study: 30596511

Group type: EXPERIMENTAL
Intervention: Vertical Simple Stitch (SS)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Modified Mason-Allen Stitch (BRUMA)
Number of subjects: 86
Study: 28043903

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily)
Number of subjects: 1092

Group type: COMPARATOR
Intervention: No prednisolone
Number of subjects: 1092
Study: 25887569

Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (CDA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Simple discectomy
Number of subjects: 24
Study: 23213075

Group type: EXPERIMENTAL
Intervention: MARS (molecular adsorbent recirculating system)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard therapy (SMT)
Number of subjects: 189
Study: 21887259

Group type: EXPERIMENTAL
Intervention: Short-bore MR scanner
Number of subjects: 174

Group type: COMPARATOR
Intervention: Open MR scanner
Number of subjects: 174
Study: 19075102

Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: simvastatin/ezetimibe 10/10 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 17824295

Group type: EXPERIMENTAL
Intervention: Carni Q-gel (2250 mg/d L-carnitine and 270 mg/d hydrosoluble ubiquinol) for 12 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Carni Q-gel
Number of subjects: 62
Study: 15648726

Group type: EXPERIMENTAL
Intervention: Secondary task that competes for left hemisphere resources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right-hemisphere task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misunderstanding of randomness
Number of subjects: 0
Study: 12017230

Group type: EXPERIMENTAL
Intervention: Direct family supervision (group 1, 7 children)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No direct supervision by a family caregiver (group 2, 5 children)
Number of subjects: 12
Study: 9793589

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 750 mg/5 mL with normal breakfast (fat content 21 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 750 mg/5 mL with Sustacal Plus (fat content 28 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atovaquone suspension 750 mg/5 mL fasting
Number of subjects: 10
Study: 7853041

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract in intensive care units
Number of subjects: 36

Group type: COMPARATOR
Intervention: Including a paper written in German
Number of subjects: 36
Study: 2239163

Group type: EXPERIMENTAL
Intervention: Single nail (Rydell)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Two hook-pins (LIH)
Number of subjects: 410